Chemistry Reference
In-Depth Information
71. Kruis, W. et al., Double-blind comparison of an oral
E
.
coli
preparation and mesalazine
in maintaining remission of ulcerative colitis,
Aliment. Pharmacol. Ther.,
11,853,1997.
72. Tursi, A. et al., Low-dose balsalazide plus a high-potency probiotic preparation is more
effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moder-
ate ulcerative colitis,
Med. Sci. Monit.,
10,PI126,2004.
73. Soo, I. et al., VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase
and reduces inflammation,
Can. J. Gastroenterol.,
22,237,2008.
74. Penner, R.M., Madsen, K.L., and Fedorak, R.N., Postoperative Crohn's disease,
Inflamm.
Bowel Dis.,
11,765,2005.
75. Marteau, P., Lemann, M., and Seksik, P., Ineffectiveness of
Lactobacillus
johnsonii
LA1
for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double-
blind, placebo-controlled GETAID trial.
Gut,
23,443,2005.
76. Lesbros-Pantoflickova, D., Corthesy-Theulaz, I., and Blum, A.L.,
Helicobacter
pylori
and probiotics,
J. Nutr.,
137,812S,2007.
77. Sabbi, T., De Angelis, P., and Dall'Oglio, L.,
Helicobacter
pylori
infection in children:
Management and pharmacotherapy,
Expert Opin. Pharmacother.,
9,577,2008.
78. Francavilla, R. et al., Inhibition of
Helicobacter pylori
infection in humans by
Lactobacillus reuteri
ATCC 55730 and effect on eradication therapy: A pilot study,
Helicobacter,
13,127,2008.
79. Felley, C.P., Corthesy-Theulaz, I., and Rivero, J.L., Favourable effect of acidified milk
(lc-1) on
H. pylori
gastritis in man,
Eur. J. Gastroenterol. Hepatol.,
13,25,2001.
80. Kalliomaki, M. and Isolauri, E., Pandemic of atopic diseases—A lack of microbial
exposure in early infancy?
Curr. Drug Targets-Infect. Disorders,
2,193,2002.
81. Noverr, M.C. and Huffnagle, G.B., Does the microbiota regulate immune responses
outside the gut?
Trends Microbiol.,
12,562,2004.
82. Furrie, E., Probiotics and allergy,
Proc. Nutr. Soc.,
64,465,2005.
83. Tang, M.L. and Robinson, M., Allergy prevention—Current recommendations and new
insights,
Aust. Fam. Physician,
37,204,2008.
84. Feleszko, W., Jaworska, J., and Hamelmann, E., Toll-like receptors—Novel tar-
gets in allergic airway disease (probiotics, friends and relatives),
Eur. J. Pharmacol.,
533,308-318,2006.
85. Vandenbulcke, L. et al., The innate immune system and its role in allergic disorders
,
Int.
Arch. Allergy Immunol.,
139,159,2006.
86. Matricardi, P.M. and Bonini, S., High microbial turnover rate preventing atopy: A
solution to inconsistencies impinging on the hygiene hypothesis?
Clin. Exp. Allergy,
30,1506,2000.
87. Morata de Ambrosini, V. et al., Study of the morphology of the cell walls of some strains
of lactic acid bacteria and related species,
J. Food Protect.,
61,557,1998.
88. Sanfilippo, L. et al.,
Bacteroides fragilis
enterotoxin induces the expression of IL-8 and
transforming growth factor-beta (TGF-β) by human colonic epithelial cells,
Clin. Exp.
Immunol.
119,456,2000.
89. Xavier, R.J. and Podolsky, DK., Microbiology: How to get along—Friendly microbes in
a hostile world,
Science,
289,1483,2000.
90. Weiner, H.L., Oral tolerance: Immune mechanisms and treatment of autoimmune dis-
eases,
Immunol. Today,
18,335,1997.
91. Niers, L.E. et al., Probiotics for cow's milk allergy: Classification after intervention,
J.
Allergy Clin. Immunol.,
115,423,2005.
92. He, F. et al., Comparison of mucosal adhesion and species identification of
Bifidobacterium
isolated from healthy and allergic infants,
FEMS Immunol. Med. Microbial.,
30,43,2001.
